Cargo Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
CARGO Therapeutics, Inc. announced a definitive merger agreement with Concentra Biosciences, LLC, following significant restructuring, workforce reductions, and the discontinuation of its lead cell therapy program.
10-Q: CARGO Therapeutics Halts Firi-Cel Development, Explores Strategic Alternatives Amidst Restructuring
CARGO Therapeutics discontinues its Phase 2 firi-cel study and suspends pipeline development, initiating a strategic review process that could lead to a reverse merger, business combination, or cash sale.
CARGO Therapeutics' Q3 2024 report highlights increased R&D spending and a net loss, but also notes sufficient cash reserves to support operations through 2026.
CARGO Therapeutics, a clinical-stage biotechnology company, reported a net loss of $44.3 million for the second quarter of 2024, alongside updates on its clinical programs and financial position.
CARGO Therapeutics reports a net loss of $35.8 million for the first quarter of 2024, alongside updates on clinical trials and financial position.